Lansing biomanufacturer to develop new vaccine


Lansing biotech company Emergent Biosolutions says it will study the development of a 'next-generation' anthrax vaccine.

The new project, which is expected to create 70 jobs, is triggered by a $186-million federal grant. Republican Congressman Mike Rogers, who toured the facility with reporters on Tuesday, says the venture could have implications in other health-related areas:

"It allows them to do a whole host of other things when it comes to biologics, for everything from tuberculosis to cancer," he says.

Rogers calls the grant a "down payment" on future security-related work at Emergent. He says the federal government considers an anthrax attack the most likely terror threat facing the country.

reWorking Michigan
For more on job creation and workforce evolution in Michigan, visit